Shots:

• Dren Bio to receive $25M up front & is eligible to receive $1B+ upon the achievement of  development, regulatory, and commercial milestones along with royalties on net sales for each target-specific product
• The collaboration will use Dren Bio’s targeted myeloid engager and phagocytosis platform to develop therapeutic bispecific Abs for select oncology targets
• Pfizer gets the right to reserve & nominate additional oncology targets & will lead the development, manufacturing, regulatory, and commercialization activities while Dren Bio obtains an exclusive right globally for the platform including all other therapeutic targets which is currently in development

Ref: Businesswire | Image: Businesswire